Asthma, Internal medicine, Immunology, Genetics and Physical therapy are his primary areas of study. His research in Asthma is mostly focused on Exhaled nitric oxide. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Placebo and Endocrinology.
His Placebo research incorporates elements of Benralizumab, Reslizumab, Surgery and Intention-to-treat analysis. Eugene R. Bleecker has researched Immunology in several fields, including Sputum and Allele. His Physical therapy research is multidisciplinary, incorporating perspectives in Body mass index, Randomized controlled trial, Intensive care medicine, COPD and Spirometry.
Eugene R. Bleecker focuses on Asthma, Internal medicine, Immunology, Genetics and COPD. His Asthma research includes themes of Placebo, Anesthesia, Intensive care medicine and Corticosteroid. His Placebo study combines topics in areas such as Benralizumab, Clinical endpoint and Adverse effect.
His research in Internal medicine intersects with topics in Gastroenterology and Endocrinology. He combines subjects such as Single-nucleotide polymorphism and Gene with his study of Immunology. His research investigates the connection between COPD and topics such as Sputum that intersect with issues in Eosinophil.
His primary areas of investigation include Asthma, Internal medicine, Immunology, COPD and Severe asthma. His biological study spans a wide range of topics, including Genome-wide association study, Exacerbation, Sputum, Corticosteroid and Cohort. His work carried out in the field of Internal medicine brings together such families of science as Placebo and Cardiology.
His research integrates issues of Expression quantitative trait loci, Gene expression and Bronchoalveolar lavage in his study of Immunology. His COPD research integrates issues from Genetic variants, Lung and FEV1/FVC ratio. His work on Benralizumab as part of general Severe asthma research is often related to HSD3B1, thus linking different fields of science.
Eugene R. Bleecker mainly focuses on Asthma, Internal medicine, COPD, Severe asthma and Genome-wide association study. Asthma is a primary field of his research addressed under Immunology. Eugene R. Bleecker has included themes like Diabetes mellitus, Gene expression and Predictive biomarker in his Immunology study.
The COPD study combines topics in areas such as Pulmonary disease, Spirometry and Lung function. His Severe asthma study integrates concerns from other disciplines, such as Eosinophil, Exhaled nitric oxide, Guideline, Respiratory system and Asthma severity. The study incorporates disciplines such as Genetic variation, Genetic association and Genetic admixture in addition to Genome-wide association study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung;Sally E. Wenzel;Jan L. Brozek;Andrew Bush.
European Respiratory Journal (2014)
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Wendy C. Moore;Deborah A. Meyers;Sally E. Wenzel;W. Gerald Teague.
american thoracic society international conference (2010)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D Pavord;Stephanie Korn;Peter Howarth;Eugene R Bleecker.
The Lancet (2012)
The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol
Harold S. Nelson;Scott T. Weiss;Eugene R. Bleecker;Steven W. Yancey.
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
Wendy C. Moore;Eugene R. Bleecker;Douglas Curran-Everett;Serpil C. Erzurum.
The Journal of Allergy and Clinical Immunology (2007)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J Mark FitzGerald;Eugene R Bleecker;Parameswaran Nair;Stephanie Korn.
The Lancet (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R Bleecker;J Mark FitzGerald;Pascal Chanez;Alberto Papi.
The Lancet (2016)
Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma
Jean Bousquet;Jean Bousquet;Eva Mantzouranis;Alvaro A. Cruz;Nadia Aït-Khaled.
The Journal of Allergy and Clinical Immunology (2010)
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations
Dara G. Torgerson;Dara G. Torgerson;Elizabeth J. Ampleford;Grace Y. Chiu;W. James Gauderman.
Nature Genetics (2011)
A genome-wide search for asthma susceptibility loci in ethnically diverse populations
David G. Marsh;Nancy E. Maestri;Linda R. Freidhoff;Kathleen C. Barnes.
Nature Genetics (1997)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: